Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment

被引：29

作者：

Liu, Yi ^{[1
,2
]}

Wang, Guohao ^{[3
]}

Zhang, Huimin ^{[2
]}

Ma, Ying ^{[2
]}

Lang, Lixin ^{[2
]}

Jacobson, Orit ^{[2
]}

Kiesewetter, Dale O. ^{[2
]}

Zhu, Lei ^{[3
]}

Gao, Shi ^{[1
]}

Ma, Qingjie ^{[1
]}

Chen, Xiaoyuan ^{[2
]}

机构：

[1] Jilin Univ, China Japan Union Hosp, Changchun 130033, Jilin, Peoples R China

[2] NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA

[3] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China

来源：

BIOCONJUGATE CHEMISTRY | 2016年 / 27卷 / 01期

基金：

美国国家卫生研究院; 美国国家科学基金会;

关键词：

ALBUMIN-BINDING; RECEPTOR; INSULIN; ANALOG; PHARMACOKINETICS; MALEIMIDES; MECHANISM; STRATEGY; AGONIST;

D O I：

10.1021/acs.bioconjchem.5b00625

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

In the treatment of type 2 diabetes mellitus, it is very important to develop therapeutics with prolonged circulation half-life. Exendin-4 is a glucagon like peptide-1 receptor (GLP-1R) agonist that has been modified in different ways for imaging insulinoma and for treating type-2 diabetes. In this work, we synthesized a maleimide derivative of truncated Evans blue dye (MEB-C3-Mal) to conjugate with (Cys(40))exendin-4 to obtain a highly stable MEB-C3-(Cys(40))exendin-4 (denoted as Abextide II). Through in situ binding with endogenous albumin, Abextide II lowers blood glucose level and prolongs the hypoglycemic effect in a type 2 diabetes mouse model more than the FDA approved Albiglutide.

引用

页码：54 / 58

页数：5

共 28 条

[1] A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis [J].

Baggio, LL ;

Huang, QL ;

Brown, TJ ;

Drucker, DJ .

DIABETES, 2004, 53 (09) :2492-2500

[2] Tunable Degradation of Maleimide-Thiol Adducts in Reducing Environments [J].

Baldwin, Aaron D. ;

Kiick, Kristi L. .

BIOCONJUGATE CHEMISTRY, 2011, 22 (10) :1946-1953

[3] β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes [J].

Butler, AE ;

Janson, J ;

Bonner-Weir, S ;

Ritzel, R ;

Rizza, RA ;

Butler, PC .

DIABETES, 2003, 52 (01) :102-110

[4] Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding [J].

Chen, Haojun ;

Wang, Guohao ;

Lang, Lixin ;

Jacobson, Orit ;

Kiesewetter, Dale O. ;

Liu, Yi ;

Ma, Ying ;

Zhang, Xianzhong ;

Wu, Hua ;

Zhu, Lei ;

Niu, Gang ;

Chen, Xiaoyuan .

THERANOSTICS, 2016, 6 (02) :243-253

[5] Albumin binding as a general strategy for improving the pharmacokinetics of proteins [J].

Dennis, MS ;

Zhang, M ;

Meng, YG ;

Kadkhodayan, M ;

Kirchhofer, D ;

Combs, D ;

Damico, LA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (38) :35035-35043

[6] Enhancing incretin action for the treatment of type 2 diabetes [J].

Drucker, DJ .

DIABETES CARE, 2003, 26 (10) :2929-2940

[7]

ENG J, 1992, J BIOL CHEM, V267, P7402

[8] Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes [J].

Feinglos, MN ;

Saad, MF ;

Pi-Sunyer, FX ;

An, B ;

Santiago, O .

DIABETIC MEDICINE, 2005, 22 (08) :1016-1023

[9]

GOKE R, 1993, J BIOL CHEM, V268, P19650

[10] The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin [J].

Havelund, S ;

Plum, A ;

Ribel, U ;

Jonassen, I ;

Volund, A ;

Markussen, J ;

Kurtzhals, P .

PHARMACEUTICAL RESEARCH, 2004, 21 (08) :1498-1504

← 1 2 3 →